Adicet Bio (NASDAQ:ACET – Free Report) had its target price reduced by Canaccord Genuity Group from $19.00 to $8.00 in a research report released on Wednesday morning, Benzinga reports. They currently have a buy rating on the stock.
Several other analysts have also commented on the stock. HC Wainwright lowered shares of Adicet Bio from a buy rating to a neutral rating in a research note on Wednesday. StockNews.com downgraded shares of Adicet Bio from a hold rating to a sell rating in a report on Tuesday, September 10th. Finally, Wedbush reiterated an outperform rating and issued a $5.00 target price on shares of Adicet Bio in a report on Tuesday, September 10th.
View Our Latest Report on ACET
Adicet Bio Stock Down 2.6 %
Adicet Bio (NASDAQ:ACET – Get Free Report) last issued its earnings results on Tuesday, August 13th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.03. Equities research analysts expect that Adicet Bio will post -1.35 EPS for the current fiscal year.
Institutional Investors Weigh In On Adicet Bio
A number of institutional investors and hedge funds have recently modified their holdings of ACET. Mirae Asset Global Investments Co. Ltd. bought a new stake in Adicet Bio in the first quarter valued at approximately $28,000. Price T Rowe Associates Inc. MD bought a new stake in Adicet Bio in the first quarter valued at approximately $37,000. Point72 DIFC Ltd increased its stake in Adicet Bio by 77.5% in the second quarter. Point72 DIFC Ltd now owns 33,441 shares of the company’s stock valued at $40,000 after purchasing an additional 14,596 shares in the last quarter. Marshall Wace LLP bought a new stake in Adicet Bio in the second quarter valued at approximately $43,000. Finally, American International Group Inc. increased its stake in Adicet Bio by 74.2% in the first quarter. American International Group Inc. now owns 26,319 shares of the company’s stock valued at $62,000 after purchasing an additional 11,214 shares in the last quarter. 83.89% of the stock is owned by institutional investors.
Adicet Bio Company Profile
Adicet Bio, Inc, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.
Further Reading
- Five stocks we like better than Adicet Bio
- What Makes a Stock a Good Dividend Stock?
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
- Most Volatile Stocks, What Investors Need to Know
- Kroger Stock is a Win-Win for Buy-and-Hold Investors
- Insider Trades May Not Tell You What You Think
- MarketBeat Week in Review – 9/9 – 9/13
Receive News & Ratings for Adicet Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adicet Bio and related companies with MarketBeat.com's FREE daily email newsletter.